Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

Cancer biology & therapy - 1 Jan 2009

Kolasa Iwona K, Rembiszewska Alina, Felisiak Anna, Ziolkowska-Seta Izabela, Murawska Magdalena, Moes Joanna, Timorek Agnieszka, Dansonka-Mieszkowska Agnieszka, Kupryjanczyk Jolanta

Abstract excerpt

PI3K/AKT signalling pathway controls important cellular processes such as the cell proliferation and apoptosis. PIK3CA gene encoding a catalytic subunit of the PI3K is mutated and/or amplified in various neoplasms, including ovarian cancer. We aimed to evaluate PIK3CA alterations and their clinical importance in ovarian cancer patients. Molecular analysis was performed on 117 ovarian carcinomas with the use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Multivariate Analysis

Share to Ovarian Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Polymorphism, Single-Stranded Conformational

Source

Identifiers

PMID: 19029838
DOI: 10.4161/cbt.8.1.7209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.PMID 19029838Read ↗

High Frequency of PIK3R1 Alterations in Ovarian Cancers: Clinicopathological and Molecular AssociationsSemantic proximity Read ↗

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathwaySemantic proximity Read ↗

Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.Semantic proximity Read ↗

Dissecting “PI3Kness”: The Complexity of Personalized Therapy for Ovarian CancerSemantic proximity Read ↗

PIK3CA alterations in Middle Eastern ovarian cancersSemantic proximity Read ↗

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.Semantic proximity Read ↗

[Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer].Semantic proximity Read ↗

Mutation of the PIK3CA gene in ovarian and breast cancer.Semantic proximity Read ↗

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.Semantic proximity Read ↗

PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.Semantic proximity Read ↗

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.Semantic proximity Read ↗

PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.